Evidence map›Paper›PMID 39459877›Full record

ArticleViruses2024

Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.

Karen Zafilaza, Jonathan Bellet, Aurélie Truffot, Vincent Foulongne, Manuela Mireille Onambele, Maud Salmona, Camille Vellas, Claire Périllaud-Dubois, Audrey Mirand, Elisabeth André-Garnier and 10 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Karen ZafilazaLaboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0009-0000-2071-9395
Jonathan BelletDépartement de Santé Publique, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.
Aurélie TruffotCentre National de la Recherche Scientifique, Commisariat à l'Energie Atomique, Institut de Recherche Interdisciplinaire de Grenoble Institut de Biologie Structurale, University Grenoble Alpes, 38000 Grenoble, France.ORCID 0000-0002-7991-1733
Vincent FoulongneLaboratoire de Virologie, Centre Hospitalier Universitaire Montpellier, 34090 Montpellier, France.ORCID 0000-0003-3741-754X
Manuela Mireille OnambeleLaboratoire de Virologie, Unité Mixte de Recherche 1137 Infection Antimicrobials Modelling Evolution, Institut Nationale de la Santé et de la Recherche Médicale, Université Paris Cité, Assistance Publique -Hôpitaux de Paris Nord Hôpital Bichat-Claude-Bernard, 75018 Paris, France.
Maud SalmonaLaboratoire de Virologie, Unité 941, Institut Nationale de la Santé et de la Recherche Médicale, Hôpital Saint-Louis, Université de Paris, Assistance Publique-Hôpitaux de Paris, 75010 Paris, France.
Camille VellasLaboratoire de virologie, Centre Hospitalier Universitaire Toulouse Purpan, Institut Nationale de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1291, 31300 Toulouse, France.ORCID 0000-0002-8637-6695
Claire Périllaud-DuboisLaboratoire de Virologie, Hôpital Universitaire Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.ORCID 0000-0003-4711-5852
Audrey MirandLaboratoire de Virologie, Centre Hospitalier Universitaire de Clermont-Ferrand, 63003 Clermont-Ferrand, France.ORCID 0000-0002-9638-2415
Elisabeth André-GarnierLaboratoire de Virologie, Centre Hospitalier Universitaire Nantes, 44000 Nantes, France.
Enagnon Kazali AlidjinouLaboratoire de Virologie, Centre Hospitalier Universitaire Lille, Université de Lille, 59000 Lille, France.
Ségolène BrichlerLaboratoire de Virologie, Hôpital Avicennes, Assistance Publique-Hôpitaux de Paris, 93000 Bobigny, France.
Honorine FenauxLaboratoire de Virologie, Centre Hospitalier Universitaire Paul Brousse, Assistance Publique-Hôpitaux de Paris, 94800 Villejuif, France.ORCID 0000-0001-7200-5976
Magali Bouvier-AliasLaboratoire de Virologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94000 Créteil, France.ORCID 0000-0003-1590-5980
Cédric HartardLaboratoire de Virologie, Centre Hospitalier Régional et Universitaire de Nancy Brabois, Laboratoire de Chimie Physique et Microbiologie pour les matériaux et l'Environnement, Centre National de la Recherche Scientifique, Université de Lorraine, 54500 Vandœuvre-lès-Nancy, France.ORCID 0000-0001-5942-2345
Céline DorivalDépartement de Santé Publique, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.
Fabrice CarratDépartement de Santé Publique, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut Nationale de la Santé et de la Recherche Médicale, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France.
Anne-Geneviève MarcelinLaboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0000-0003-4808-8999
Karl SteficLaboratoire de Virologie, Centre Hospitalier et Régional Universitaire de Tours, Unité 1259, Institut Nationale de la Santé et de la Recherche Médicale, 37000 Tours, France.ORCID 0000-0002-9686-9194
Cathia SoulieLaboratoire de Virologie, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université, Assitance Publique-Hôpitaux de Paris, 75013 Paris, France.ORCID 0009-0008-2032-4148

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors.

methodsThe COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021).

resultsThe study included 1004 patients with COVID-19, of whom 691 received Bamlanivimab/Etesevimab and 313 received Casirivimab/Imdevimab. The alpha variant represented 90.1% of those for whom data were available. The risk of hospitalization within 30 days was lower with Bamlanivimab/Etesevimab (12.7%, CI 95% [9.9-16.3%]) compared to Casirivimab/Imdevimab (28.4%, CI 95% [22.7-35.1%) (

conclusionsA higher rate of hospitalization was seen with Casirivimab/Imdevimab (RONAPREVE

Indexed as

Antibodies, Monoclonal, HumanizedCOVID-19 Drug TreatmentSARS-CoV-2Spike Glycoprotein, CoronavirusAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsCOVID-19Drug CombinationsFemaleHospitalizationHumansMaleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral Agentsbamlanivimabbamlanivimab and etesevimab drug combinationcasirivimabcasirivimab and imdevimab drug combinationDrug CombinationsetesevimabSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19immune escape mutationmonoclonal antibody therapySARS-CoV-2spike gene

Identifiers

PMID39459877
PMCPMC11512400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.